Development and Validation of Novel Residual Risk Scores for Patients With ASCVD
RRS16 and RRS24 outperformed AHA guideline model in estimating the residual risk in patients with established ASCVD. Both are clinically applicable but require further validation in diverse populations.
Authors
- Olga Mineeva (ORCID: https://orcid.org/0000-0002-5669-3497)
- Vadim Bubes
- Samia Mora (ORCID: https://orcid.org/0000-0001-6283-0980)
- Olga Demler (ORCID: https://orcid.org/0000-0003-3355-3210)
- Chunying Li (ORCID: https://orcid.org/0000-0002-2558-6971)
- Franco Giulianini
- Simeon Häfliger
- Gunnar Raetsch
Institutions
- Brigham and Women's Hospital (US)
- ETH Zurich (CH)
Publication Details
- Journal
- JACC Advances
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1016/j.jacadv.2025.102162
- Citations
- 2
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.74